Lobo Genetics

lobogene.com

Lobo Genetics enables safer cannabis use through DNA testing. Consumers and patients can gain actionable insights into their personal response to cannabis based on their genetic profile. Lobo's portable device platform provides results in under an hour, and can be deployed in medical clinics, dispensaries, pharmacies or retail outlets. With applications across the recreational, medical and clinical space, Lobo is bringing the science of cannabis genetics to everyone.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

SARTORIUS STEDIM BIOTECH COMPLETES ACQUISITION OF NOVASEP'S CHROMATOGRAPHY DIVISION

Sartorius Stedim Biotech S.A. | February 08, 2022

news image

Sartorius Stedim Biotech, a leading partner of the biopharma industry, announced today that it closed the acquisition of the Novasep chromatography division as of February 7, 2022, following approval by the U.S. Federal Trade Commission. The transaction had already been agreed upon at the beginning of 2021. The business acquired generated sales of around 40 million euros in 2020 at a double-digit profit margin; final figures for 2021 are not yet available. The majority of the approximately 100 e...

Read More

MEDICAL

YESCARTA® RECEIVES U.S. FDA APPROVAL AS FIRST CAR T-CELL THERAPY FOR INITIAL TREATMENT OF RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (LBCL)

LBCL | April 04, 2022

news image

Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved Yescarta® (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Yescarta demonstrated a clinically meaningful and statistically significant improvement in event-free survival (EFS; hazard ratio 0.398; P< 0.0001) over the cur...

Read More

INDUSTRIAL IMPACT

CYBIN ANNOUNCES ADDITIONAL ADELIA MILESTONE ACHIEVEMENT

Cybin Inc. | January 28, 2022

news image

Cybin Inc. a biotechnology company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that Adelia Therapeutics Inc. a wholly-controlled subsidiary of Cybin, has achieved the milestones identified as Y1, Q4 (iv), Y1, Q4 (v) and Y2, Q1 (vi) as contemplated by the terms of a contribution agreement dated December 4, 2020 among Cybin, Cybin Corp., Cybin US Holdings Inc. a wholly-controlled subsidiary of Cybin, and all of the previous shareholders of Adelia.
Read More

INDUSTRIAL IMPACT

NUCLERA ANNOUNCES EXPANSION WITH NEW US SUBSIDIARY

Nuclera | January 19, 2022

news image

Nuclera, a UK-based biotech company developing cutting-edge benchtop protein printing technologies, announces the opening of its US subsidiary in Boston, MA. The addition of this US facility in the rapidly growing biotechnology hub of greater Boston is a critical step in the company’s plans, paving the way for Nuclera’s revolutionary eProteinTM desktop bioprinter—that offers unprecedented speed and convenience for biotherapeutics, agribiotech and other markets of...

Read More
news image

INDUSTRIAL IMPACT

SARTORIUS STEDIM BIOTECH COMPLETES ACQUISITION OF NOVASEP'S CHROMATOGRAPHY DIVISION

Sartorius Stedim Biotech S.A. | February 08, 2022

Sartorius Stedim Biotech, a leading partner of the biopharma industry, announced today that it closed the acquisition of the Novasep chromatography division as of February 7, 2022, following approval by the U.S. Federal Trade Commission. The transaction had already been agreed upon at the beginning of 2021. The business acquired generated sales of around 40 million euros in 2020 at a double-digit profit margin; final figures for 2021 are not yet available. The majority of the approximately 100 e...

Read More
news image

MEDICAL

YESCARTA® RECEIVES U.S. FDA APPROVAL AS FIRST CAR T-CELL THERAPY FOR INITIAL TREATMENT OF RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (LBCL)

LBCL | April 04, 2022

Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved Yescarta® (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Yescarta demonstrated a clinically meaningful and statistically significant improvement in event-free survival (EFS; hazard ratio 0.398; P< 0.0001) over the cur...

Read More
news image

INDUSTRIAL IMPACT

CYBIN ANNOUNCES ADDITIONAL ADELIA MILESTONE ACHIEVEMENT

Cybin Inc. | January 28, 2022

Cybin Inc. a biotechnology company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that Adelia Therapeutics Inc. a wholly-controlled subsidiary of Cybin, has achieved the milestones identified as Y1, Q4 (iv), Y1, Q4 (v) and Y2, Q1 (vi) as contemplated by the terms of a contribution agreement dated December 4, 2020 among Cybin, Cybin Corp., Cybin US Holdings Inc. a wholly-controlled subsidiary of Cybin, and all of the previous shareholders of Adelia.
Read More

news image

INDUSTRIAL IMPACT

NUCLERA ANNOUNCES EXPANSION WITH NEW US SUBSIDIARY

Nuclera | January 19, 2022

Nuclera, a UK-based biotech company developing cutting-edge benchtop protein printing technologies, announces the opening of its US subsidiary in Boston, MA. The addition of this US facility in the rapidly growing biotechnology hub of greater Boston is a critical step in the company’s plans, paving the way for Nuclera’s revolutionary eProteinTM desktop bioprinter—that offers unprecedented speed and convenience for biotherapeutics, agribiotech and other markets of...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us